Key Developments: Diagnos Inc (ADK.V)

ADK.V on TSX Venture Exchange

0.09CAD
1 May 2015
Change (% chg)

$-0.00 (-5.56%)
Prev Close
$0.09
Open
$0.09
Day's High
$0.09
Day's Low
$0.09
Volume
15,000
Avg. Vol
268,236
52-wk High
$0.12
52-wk Low
$0.04

Search Stocks

Latest Key Developments (Source: Significant Developments)

Diagnos Inc announces licensing deal with Clinique Hamouche in Algeria
Tuesday, 14 Apr 2015 09:00am EDT 

Diagnos Inc:Announces Licensing Deal With Clinique Hamouche in Algeria.Says it will be providing it's proprietary telemedicine software, CARA, and retina image interpretation to help clinic in adding an additional service for it's patients, retina screening.Preliminary contract is valid for one year with possibility for renewal and expansion.  Full Article

Diagnos Inc announces two year renewal of successful program in UAE
Thursday, 26 Mar 2015 09:47am EDT 

Diagnos Inc:Says renewal of agreement originally announced on March 14, 2012 that has since been renewed and expanded to a total of fourteen mobile screening units.Says value of two year agreement is about C$716,000.  Full Article

Diagnos Inc announces first screening project in Poland with pharmaceutical Company
Wednesday, 18 Mar 2015 12:57pm EDT 

Diagnos Inc:signs contract with a large global pharmaceutical company that markets a leading ophthalmology product indicated for a variety of ophthalmic complications, including those associated with diabetes, for a screening project in Poland.Says this project is in conjunction with the same global pharmaceutical company that DIAGNOS works with around the world, including the UAE and India.According to the International Diabetes Federation, there are over two mln people suffering from diabetes in Poland.Following clinical guidelines, 100 pct of this diabetic population should have their retinas screened yearly, but, currently, only a small proportion of the population is.  Full Article

Diagnos announces contract with a Ophthalmology Pharmaceutical Company in USA
Tuesday, 10 Mar 2015 11:05am EDT 

Diagnos Inc:Says the close of a commercial agreement to provide retina screening services to patients in the United States.Sponsor of the services is a major U.S.-based pharmaceutical company that markets a ophthalmology product indicated for a variety of ophthalmic complications including those associated with diabetes.  Full Article

Diagnos Inc opens Mexican Subsidiary Diagnos Internacional, S.A. de C.V
Tuesday, 25 Nov 2014 09:30am EST 

Diagnos Inc:Says opening of its Mexican Subsidiary, Diagnos Internacional, S.A. de C.V.  Full Article

Diagnos Inc announces contract with Dr. Kovil's Diabetes Care Centre in Mumbai
Tuesday, 16 Sep 2014 02:00pm EDT 

Diagnos Inc:Says signing of contract with Dr. Kovil's Diabetes Care Centre in Mumbai for one retinopathy screening unit.  Full Article

Diagnos announces contract with Vishal Gupta's Diabetes and Endocrine Clinic in Mumbai
Tuesday, 9 Sep 2014 09:00am EDT 

Diagnos Inc:Diagnos Healthcare India Pvt. Ltd announces signing of contract with Dr. Vishal Gupta's Diabetes and Endocrine Clinic in Mumbai for one retinopathy screening unit.Clinic offers multiple services to people suffering from diabetes, including, but not limited to, diabetes risk assessment, consultation with an endocrinologist, consultation with dietician, and diabetes education.  Full Article

Diagnos Inc announces first retinopathy screening unit in Turkey
Wednesday, 3 Sep 2014 10:02am EDT 

Diagnos Inc:Signs contract with large global pharmaceutical company for screening project in Turkey.  Full Article

Diagnos Inc announces signing of contract with Ministry of Health Owned Medical Center in United Arab Emirates
Wednesday, 16 Jul 2014 09:30am EDT 

Diagnos Inc:Signing of contract with Al Manama Medical Center for deployment of screening unit and usage of CARA in Unite Arab Emirates, project fully supported by the UAE Ministry of Health.  Full Article

Diagnos completes merger with Warnex Inc
Tuesday, 8 Jul 2014 03:34pm EDT 

Diagnos Inc:Announces the closing of the merger of Warnex Inc. ("WARNEX") with a wholly-owned subsidiary of DIAGNOS initially announced on May 5.Says it will issue 28,323,884 common shares to the shareholders of WARNEX and 1,875,000 stock warrants (the "Diagnos Warrants") to Persistence Capital Partners.  Full Article

Search Stocks